Biobizkaia
Ikerketa zentroa
Dana–Farber Cancer Institute
Boston, Estados UnidosDana–Farber Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (9)
2022
2021
-
Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia
The Lancet Haematology, Vol. 8, Núm. 7, pp. e513-e523
2016
2015
-
Management and Outcome of Patients With Langerhans Cell Histiocytosis and Single-Bone CNS-Risk Lesions: A Multi-Institutional Retrospective Study
Pediatric Blood and Cancer, Vol. 62, Núm. 12, pp. 2162-2166
2007
-
Structures of T Cell Immunoglobulin Mucin Protein 4 Show a Metal-Ion-Dependent Ligand Binding Site where Phosphatidylserine Binds
Immunity, Vol. 27, Núm. 6, pp. 941-951
1995
-
Molecular characterization of the human transmembrane protein-tyrosine phosphatase δ: Evidence for tissue-specific expression of alternative human transmembrane protein-tyrosine phosphatase δ isoforms
Journal of Biological Chemistry, Vol. 270, Núm. 12, pp. 6722-6728
-
The LAR/PTPδ/PTPσ subfamily of transmembrane protein-tyrosine-phosphatases: Multiple human LAR, PTPδ, and PTPσ isoforms are expressed in a tissue-specific manner and associate with the LAR-interacting protein LIP.1
Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, Núm. 25, pp. 11686-11690
1992
-
Functional role of α2/β1 and α4/β1 integrins in leukocyte intercellular adhesion induced through the common β1 subunit
European Journal of Immunology, Vol. 22, Núm. 12, pp. 3111-3119